These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16575759)

  • 41. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.
    Morgenthaler NG; Nagata A; Katayama S; Bergmann A; Iitaka M
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):193-8. PubMed ID: 12153597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?
    Kabadi UM; Premachandra BN
    Endocr Pract; 2007 Oct; 13(6):615-9. PubMed ID: 17954417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H; Bech K; Siersbaek-Nielsen K; Friis T
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations.
    Foley TP; White C; New A
    J Pediatr; 1987 Mar; 110(3):378-86. PubMed ID: 2880956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.
    Szabó J; Leövey A; Karányi Z; Várvölgyi C; Fórizs E; Herceg L
    Acta Med Hung; 1989; 46(1):23-30. PubMed ID: 2570399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey.
    Yoshida K; Aizawa Y; Kaise N; Fukazawa H; Kiso Y; Sayama N; Mori K; Hori H; Abe K
    J Endocrinol Invest; 1996 Nov; 19(10):682-6. PubMed ID: 9007700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.
    Kung AW; Jones BM
    J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences in the levels of TSH-binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of L-thyroxine therapy.
    Khoo DH; Eng PH; Ho SC; Fok AC
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):73-9. PubMed ID: 10468968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.
    Kazuo K; Fujikado T; Ohmi G; Hosohata J; Tano Y
    Br J Ophthalmol; 1997 Dec; 81(12):1080-3. PubMed ID: 9497469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.
    Eckstein AK; Plicht M; Lax H; Neuhäuser M; Mann K; Lederbogen S; Heckmann C; Esser J; Morgenthaler NG
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3464-70. PubMed ID: 16835285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hashimoto's thyroiditis with heterogeneous antithyrotropin receptor antibodies: unique epitopes may contribute to the regulation of thyroid function by the antibodies.
    Akamizu T; Kohn LD; Hiratani H; Saijo M; Tahara K; Nakao K
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2116-21. PubMed ID: 10852437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the ratio of T3 release stimulating antibodies to TSH-binding inhibiting antibodies during the course of Graves' disease.
    Hoermann R; Saller B; Mann K
    Horm Metab Res; 1990 Mar; 22(3):183-7. PubMed ID: 1971613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A rapid homogenous bioassay for detection of thyroid-stimulating antibodies based on a luminescent cyclic AMP biosensor.
    Miao LY; Kim HJ; Whitlatch K; Jaiswal D; Navarro A; Egan R; Olivo PD
    J Immunol Methods; 2022 Feb; 501():113199. PubMed ID: 34871593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurement of thyroid stimulating immunoglobulins using a novel thyroid stimulating hormone receptor-guanine nucleotide-binding protein, (GNAS) fusion bioassay.
    Pierce M; Sandrock R; Gillespie G; Meikle AW
    Clin Exp Immunol; 2012 Nov; 170(2):115-21. PubMed ID: 23039881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The assay for thyroid stimulating immunoglobulins using cultured human thyroid cells.
    Grant SJ; Luttrell BM; Hales IB
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):325-34. PubMed ID: 2866050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
    Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.